The Florence Register of amyloidosis: 20 years' experience in the diagnosis and treatment of the disease in the Florence district area

Cania, A.; Bergesio, Franco; Curciarello, Giuseppe; Perfetto, Federico; Ciciani, Anna Maria; Nigrelli, Santi; Minuti, Barbara; Caldini, A. L.; Lollo, Simonetta Di; Nozzoli, Chiara; Salvadori, Maurizio

doi:10.3109/13506129.2011.574354031

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 A recent single-center study detailing 20 years' Florentine experience of AA amyloidosis showed that rheumatoid arthritis contributed to 45% of cases and 67% of patients had some form of renal involvement. 4 Other recent studies have shown that 5%-17% of patients with rheumatoid arthritis have amyloidosis reported as the cause of death. 5 In a study of 374 patients with AA amyloidosis, Lachmann et al reported that patients can experience symptoms of inflammatory disease for a median duration of approximately 17 years before a diagnosis of amyloidosis is made.…”

Section: Introductionmentioning

confidence: 97%

Review of eprodisate for the treatment of renal disease in AA amyloidosis

Rumjon¹,

Coats²,

Javaid³

2012

IJNRD

View full text Add to dashboard Cite

Secondary (AA) amyloidosis is a multisystem disorder complicating chronic infections or inflammatory diseases. It is characterized by extracellular deposit of fibrils composed of fragments of serum amyloid A (SAA), an acute phase reactant protein. The kidney is the most frequent organ involved, manifesting as progressive proteinuria and renal impairment. Attenuation of the level of circulating SAA protein by treating the underlying inflammatory condition remains the primary strategy in treating AA amyloidosis. However, at times, achieving adequate control of protein production can prove difficult. In addition, relapse of renal function often occurs rapidly following any subsequent inflammatory stimulus in patients with existing amyloidosis. Recently there has been an interest in finding other potential strategies targeting amyloid deposits themselves. Eprodisate is a sulfonated molecule with a structure similar to heparan sulfate. It competitively binds to the glycosaminoglycan-binding sites on SAA and inhibits fibril polymerization and amyloid deposition. Recent randomized clinical trial showed that it may slow down progressive renal failure in patients with AA amyloidosis. However confirmatory studies are needed and results of a second Phase III study are eagerly awaited to clarify whether or not eprodisate has a place in treating renal amyloid disease.

show abstract

Section: Introductionmentioning

confidence: 97%